With a mission to extend and enhance human life, the Bristol-Myers Squibb Company has a long-standing reputation for providing quality information to both patients and the medical profession about its range of highly specialised pharmaceutical medications. This commitment is demonstrated in the area of oncology, where the company's Australian division, Bristol-Myers Squibb Pharmaceuticals, is proud to sponsor the Society's information and education content about ovarian cancer.

Operating from Noble Park, Victoria, Bristol-Myers Squibb Pharmaceuticals manufactures and markets prescription and consumer medicines in therapeutic areas covering cancer; cardiovascular disease; neuroscience; dermatology; immunology; pain management and infectious diseases.

In the area of ovarian cancer, Bristol-Myers Squibb produces the leading medication Taxol™ (paclitaxel). Developed following the amazing discovery of the therapeutic qualities of the bark of the Pacific Yew tree, Taxol™ is a chemotherapy treatment for various types of cancer, particularly ovarian and breast cancers."